

**Relationship between Dyslipidemia and Hyperglycemia in Obese Patients**Hossam B. Bahnasy<sup>1\*</sup>, El-Mahdi Mohamed<sup>2</sup><sup>1</sup>Head of public Health Department and Member of Medical laboratory Department, Faculty of Health sciences, Omar Al-Moukhtar University, Libya<sup>2</sup>Medical laboratory Department, Faculty of Health sciences, Omar Al-Moukhtar University, LibyaCorresponding Author: Hossam B. Bahnasy | **Received:** 11.11.2025 | **Accepted:** 14.12.2025 | **Published:** 02.01.2026

**Abstract:** Obesity occurs because of the accumulation of fat in the body and can occur due to high cholesterol so that it can interfere with health. This study aims to provide an overview of triglycerides (S.TG), cholesterol (S.TC), fasting blood sugars (FBG) and glycated hemoglobin (HbA1c) in obese patients. This method is by calculating the Body Mass Index (BMI), S.TG, S.TC, FBG and HbA1c examination. The data obtained were then analyzed descriptively. Based on this research, it was found that most obese patients had high cholesterol levels (101-256 mg/dL) while overweight patients showed moderate cholesterol levels (135-210 mg/dL). In addition, upon triglyceride examination the majority overweight patients still had normal levels (<150 mg/dL) while the obese patients showed high levels (88-300 mg/dl). Moreover, the obese patients manifested high glucose levels (84-413 mg /dl) as well as overweight patients (300-380 mg/dl). Finally, it was found that the obese patients had high glycated hemoglobin (HbA1c) levels (6.10-13.8) as well as overweight patients (9.60-14.0).

**Keywords:** Obesity, Overweight, Triglycerides, Cholesterol, Fasting Blood Glucose, HbA1c.

**Citation:** Hossam B. Bahnasy *et al.* Relationship between Dyslipidemia and Hyperglycemia in Obese Patients. Grn Int J Apl Med Sci, 2026 Jan-Feb 4(1): 6-9.

**INTRODUCTION**

Obesity can occur because the energy intake that enters the body is greater than the energy expended. So that excess energy will be stored as fat in the cells, and can cause weight gain [1]. Obesity is considered as one of the factors that can increase the prevalence of hypertension, glucose intolerance, and atherosclerotic coronary heart disease in obese patients [2-4]. Obesity can occur because of high cholesterol which is considered bad for health. The types of cholesterol in our body are LDL (Low Density Lipoprotein) which can stick to blood vessels and HDL (High Density Lipoprotein) which is fat that can dissolve LDL content in the body. While the total amount of cholesterol in the body is called total cholesterol [5]. Obesity has a close relationship with the high incidence of cardiovascular disease. Body metabolism and heart performance will be disrupted when LDL levels in the body's blood are more than HDL levels. HDL referred to as the good fat, because it cleans LDL-cholesterol from the walls of blood vessels by transporting it back to the liver [6,7]. HbA1c was used as an indicator of glycemic control in most previous studies. HbA1c was a stable indicator of glycemic control, which reflected an average glycemic level of about three months and did not show glycemic

variability over a period of time. Fasting blood glucose (FBG) is an economical and important indicator for the diagnosis and glycemic variability. Few studies have shown the relationship between glycemic profile (FBG, HbA1c) control and lipid profiles (S.TG, S.TC) [8-10]. In addition these studies confirmed the relationship between glycemic control and lipid profiles in patients, their results are quite inconsistent [11-14]. Therefore, this study aims to assess the levels of lipid profiles (S.TG, S.TC) and glycemic profile (FBG and HbA1c) and investigate the relationship between glycemic profile control and lipid profile in overweight and obese patients.

**RESEARCH METHODS**

This study aims to provide an overview of S.TG, S.TC, FBG, and HbA1c in obese patients. The sample of this study was 50 respondents consisting of men and women aged 50 to 65 years who have obesity with BMI 30 Kg/m<sup>2</sup>. The procedures of this research include: (1) Body Mass Index (BMI) calculation by measuring height, body weight, then calculating the BMI formula; (2) S.TG, S.TC measurement and (3) FBG, and HbA1c measurement. The data obtained were then analyzed descriptively.

**RESULTS**

**Table (1): Distribution of the studied cases according to BMI (n=50)**

	No.	%
<b>BMI (kg/m<sup>2</sup>)</b>		
25 – 29.9 (overweight)	4	8.0
>30 (obese)	46	92.0

The distribution of lipid profile in overweight and obese patients is listed on tables below.

**Table (2): Relation between BMI and S. Cholesterol**

S. Cholesterol (mg /dl)	BMI (kg/m <sup>2</sup> )				Test of sig.	P
	25 – 29.9 (overweight) (n=3)		>30 (obese) (n=21)			
	No.	%	No.	%		
≤ 200 (Normal)	2	66.7	14	66.7	□□□	<sup>FE</sup> p=1.000
> 200 (Abnormal)	1	33.3	7	33.3	0.0	
Min. – Max.	135.0 – 210.0		101.0 – 256.0		t=	0.876
Mean ± SD.	166.0 ± 39.15		170.41 ± 45.67		0.158	
Median (IQR)	153.0 (144.0 – 181.5)		175.0 (128.0 – 209.0)			

IQR: Inter quartile range      SD: Standard deviation  
 χ<sup>2</sup>: Chi square test      FE: Fisher Exact      t: Student t-test  
 p: p value for comparing between the studied BMI groups

**Table (3): Relation between BMI and S.TG**

S.TG (mg /dl)	BMI (kg/m <sup>2</sup> )				Test of sig.	P
	25 – 29.9 (overweight) (n=2)		>30 (obese) (n=17)			
	No.	%	No.	%		
≤ 150 (Normal)	2	100.0	8	47.1	□□□	<sup>FE</sup> p=0.474
>150 (Abnormal)	0	0.0	9	52.9	2.012	
Min. – Max.	88.0 – 138.0		32.0 – 300.0		t=	0.561
Mean ± SD.	113.0 ± 35.36		146.31 ± 76.87		0.594	
Median (IQR)	113.0 (88.0 – 138.0)		154.0 (95.0 – 193.0)			

IQR: Inter quartile range      SD: Standard deviation  
 χ<sup>2</sup>: Chi square test      FE: Fisher Exact      t: Student t-test  
 p: p value for comparing between the studied BMI groups

The distribution of glycaemia profile in overweight and obese patients is listed on tables below.

**Table (2): Relation between BMI and FBS**

FBS (mg /dl)	BMI (kg/m <sup>2</sup> )				Test of sig.	P
	25 – 29.9 (overweight) (n=4)		>30 (obese) (n=45)			
	No.	%	No.	%		
≤ 126 (Normal)	0	0.0	10	22.2	□□□	<sup>FE</sup> p=0.569
>126 (Abnormal)	4	100.0	35	77.8	□□□□□	
Min. – Max.	300.0 – 380.0		84.0 – 413.0		t=	0.002*
Mean ± SD.	330.0 ± 38.30		198.20 ± 80.82		3.206*	
Median (IQR)	320.0 (300.0–360.0)		188.0 (130.0–254.0)			

IQR: Inter quartile range      SD: Standard deviation  
 χ<sup>2</sup>: Chi square test      FE: Fisher Exact      t: Student t-test  
 p: p value for comparing between the studied BMI groups  
 \*: Statistically significant at p ≤ 0.05

**Table (3): Relation between BMI and HbA1C %**

HbA1C (%)	BMI (kg/m <sup>2</sup> )				Test of sig.	P
	25 – 29.9 (overweight) (n=4)		>30 (obese) (n=44)			
	No.	%	No.	%		
≤ 6.5 (Normal)	0	0.0	5	11.4	□□□	<sup>FE</sup> p=
> 6.5 (Abnormal)	4	100.0	39	88.6	□□□□□	1.000
Min. – Max.	9.60 – 14.0		6.10 – 138.00		U=	0.010*
Mean ± SD.	12.78 ± 2.13		12.22 ± 19.52		22.50*	
Median (IQR)	13.75 (11.55 – 14.0)		9.10 (7.50 – 11.20)			

IQR: Inter quartile range

SD: Standard deviation

 $\chi^2$ : Chi square test

FE: Fisher Exact

U: Mann Whitney test

p: p value for comparing between the studied BMI groups

\*: Statistically significant at  $p \leq 0.05$ 

## DISCUSSION

On examination of cholesterol levels, it was found that most obese patients were known to have high cholesterol levels (101- 256 mg/dL) and with overweight patients moderate cholesterol levels (135-210 mg/dL). Triglyceride examination in overweight patients showed that the majority still had normal levels (<150 mg/dL). Triglyceride examination in obese patients showed that high levels (88-300 mg/dL). Our results manifested the association between obesity and serum cholesterol level and triglyceride level while it was weaker in upper age and less in young age. So it is recommended to establish an educational planning for controlling the obesity, cholesterol and triglycerides especially in early middle age.

On examination of fasting blood glucose levels, it was found that the obese patients were known to have high glucose levels (84-413 mg/dl) and in overweight patients (300-380 mg/dl).

On examination of glycated hemoglobin (HbA1C) levels, it was found that the obese patients were known to have high (HbA1C) levels (6.10- 13.8) and in overweight patients (9.60-14.0).

## CONCLUSION

Hyperlipidemia and hyperglycemia is a major health problem in the east of Libya and obesity is associated with it. There is significant association between serum cholesterol level, triglycerides levels and hyperglycemia and obesity.

**Acknowledgement:** None**Conflict of Interest:** The authors declare no conflict of interest.**Source of Fund:** None

## REFERENCES

1. Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. *JAMA* 2012;308: 1150–1159
2. who.int/zh/news-room/fact-sheets/detail/obesity-and-overweight[Internet]. World Health Organization. World Obesity Federation. 2018 [cited 2018 Feb 16]. Available from: <https://www.who.int/zh/news-room/fact-sheets/detail/obesity-and-overweight>.
3. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. *N Engl J Med* 2017;376:254–266 .
4. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism*. 2019; 92:6–10. <https://doi.org/10.1016/j.metabol.2018.09.005> PMID : 30253139
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143-421.
6. Henriksson KM, Lindblad U, Agren B, Nilsson-Ehle P, Råstam L. Associations between body height, body composition and cholesterol levels in middle-aged men. The coronary risk factor study in southern Sweden (CRISS). *Eur J Epidemiol* 2001;17:521-6.
7. Chuanlei Zheng , Yanhong Liu , Cong Xu , Shaobo Zeng, Qi Wang , Yixing Guo , Jian Li , Sisi Li, Minghua Dong , Xiaoting Luo & Qingfeng Wu . Association between obesity and the prevalence of dyslipidemia in middle-aged and older people: an observational study. *Scientific Reports* 2024;14:11974
8. Bergental, R.M.; Gal, R.L.; Connor, C.G.; Gubitosi-Klug, R.; Kruger, D.; Olson, B.A.; Willi, S.M.; Aleppo, G.; Weinstock, R.S.; Wood, J.; et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. *Ann. Intern. Med.* 2017, 167, 95–102. [CrossRef] [PubMed].
9. Artha, I.M.J.R.; Bhargah, A.; Dharmawan, N.K.; Pande, U.W.; Triyana, K.A.; Mahariski, P.A.;



- Yuwono, J.; Bhargah, V.; Prabawa, I.P.Y.; Manuaba, I.B.A.P.; et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. *Vasc. Health Risk Manag.* 2019, 15, 149–157. [CrossRef].
10. Sherpa LY, Deji, Stigum H, Chongsuvivatwong V, Luobu O, Thelle DS, et al. Lipid profile and its association with risk factors for coronary heart disease in the highlanders of Lhasa, Tibet. *High Alt Med Biol* 2011;12:57-63.
11. Laverdy, O.G.; Hueb, W.A.; Sprandel, M.C.; Kalil-Filho, R.; Maranhão, R.C. Effects of glycemic control upon serum lipids and lipid transfers to HDL in patients with type 2 diabetes mellitus: Novel findings in unesterified cholesterol status. *Exp. Clin. Endocrinol. Diabetes* 2015, 123, 232–239. [CrossRef].
12. Zhu, H.T.; Yu, M.; Hu, H.; He, Q.F.; Pan, J.; Hu, R.Y. Factors associated with glycemic control in community-dwelling elderly individuals with type 2 diabetes mellitus in Zhejiang, China: A cross-sectional study. *BMC. Endocr. Disord.* 2019, 19, 57. [CrossRef] [PubMed].
13. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2018. *Diabetes care* 2018, 41, S55-S64. (CrossRef)(PubMed).
14. Stephanie T. Chung, Lorraine E. Levitt Katz, Nicolas Stettler-Davis, Justine Shults, Arthur Sherman, Joon Ha, Darko Stefanovski, Ray C. Boston, Daniel J. Rader, and Sheela N. Magge. The Relationship Between Lipoproteins and Insulin Sensitivity in Youth With Obesity and Abnormal Glucose Tolerance. *The Journal of Clinical Endocrinology & Metabolism*, 2022, 107, 1541–1551.

